Prosecution Insights
Last updated: October 01, 2026

Examiner: LI, BAO Q

Tech Center 1600 • Art Units: 1648 1654 1671 1675

This examiner grants 75% of resolved cases

Analysis

Bao Q Li is an examiner in Tech Center 1600, specifically within Art Unit 1648. The examiner has 912 resolved cases. This volume of work has resulted in an allowance rate pct of 75.4. For practitioners, this allowance rate pct serves as an indicator of the outcome frequency for applications assigned to this docket. The data also reveals an interview lift pct of 26.8. This interview lift pct suggests that conducting an interview is a strategy associated with an increased probability of allowance. Applications that reach a grant do so with a median days to allowance of 1037.

The 1037 median days to allowance provides a timeline for the patent acquisition process. By analyzing the 912 resolved cases, one can see the historical record of practice in Art Unit 1648. The 75.4 allowance rate pct and 26.8 interview lift pct provide metrics for evaluating the prosecution environment. These figures assist in the development of a strategy for patent applications. Understanding these data points is useful for managing expectations and resources during the examination phase.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

75.4%
Allow Rate
+15.4% vs TC avg
933
Total Applications
+26.8%
Interview Lift
1037
Avg Prosecution Days
Based on 912 resolved cases, 2023–2026

Rejection Statute Breakdown

3.5%
§101 Eligibility
26.6%
§102 Novelty
22.5%
§103 Obviousness
26.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18846449 NOVEL USAGE OF ONCOLYTIC GENE-MODIFIED MEASLES VIRUS Non-Final OA The University of Tokyo
18250471 VIRAL VECTORS ENCODING CANINE INSULIN FOR TREATMENT OF METABOLIC DISEASES IN DOGS Non-Final OA The Trustees of the University of Pennsylvania
18282739 SIZE EXCLUSION CHROMATOGRAPHY ANALYSIS OF EMPTY AND FULL AAV CAPSIDS Non-Final OA Genzyme Corporation
18252790 DESIGN OF OPTIMIZED UNIVERSAL INFLUENZA VACCINES, THEIR DESIGNS AND USES Final Rejection Greffex, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month